2019 Q1 Form 10-K Financial Statement
#000156459019006999 Filed on March 08, 2019
Income Statement
| Concept | 2019 Q1 | 2018 | 2017 Q4 |
|---|---|---|---|
| Revenue | $5.000M | $2.840M | $1.622M |
| YoY Change | 430.79% | -46.83% | -60.05% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $3.940M | $15.71M | $2.850M |
| YoY Change | 3.14% | 34.73% | -10.94% |
| % of Gross Profit | |||
| Research & Development | $16.15M | $50.31M | $12.28M |
| YoY Change | 92.24% | -6.23% | 17.41% |
| % of Gross Profit | |||
| Depreciation & Amortization | $351.0K | $1.778M | $400.0K |
| YoY Change | -37.66% | 26.82% | 566.67% |
| % of Gross Profit | |||
| Operating Expenses | $20.09M | $66.02M | $15.13M |
| YoY Change | 64.37% | 1.08% | 10.76% |
| Operating Profit | -$15.09M | -$63.18M | -$13.51M |
| YoY Change | 33.77% | 5.35% | 40.71% |
| Interest Expense | $360.0K | $870.0K | $130.0K |
| YoY Change | 111.76% | 35.94% | -31.58% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $316.0K | $478.0K | -$43.00K |
| YoY Change | 251.11% | -578.0% | 437.5% |
| Pretax Income | -$14.42M | -$61.83M | -$13.42M |
| YoY Change | 30.73% | 4.04% | 42.46% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$14.42M | -$61.83M | -$13.42M |
| YoY Change | 30.76% | 4.04% | 42.55% |
| Net Earnings / Revenue | -288.36% | -2177.18% | -827.62% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$5.655M | -$32.20M | -$10.17M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 51.04M | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q1 | 2018 | 2017 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $105.3M | $118.4M | $74.50M |
| YoY Change | 66.35% | 58.93% | -12.87% |
| Cash & Equivalents | $32.41M | $28.80M | $29.72M |
| Short-Term Investments | $73.70M | $89.60M | $44.70M |
| Other Short-Term Assets | $3.100M | $2.500M | $1.700M |
| YoY Change | 34.78% | 47.06% | -58.54% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $108.5M | $120.9M | $76.13M |
| YoY Change | 65.4% | 58.87% | -15.63% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $14.10M | $14.50M | $424.0K |
| YoY Change | -9.62% | 1511.11% | -21.63% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $900.0K | $800.0K | $33.00K |
| YoY Change | 3650.0% | -52.94% | -51.47% |
| Total Long-Term Assets | $15.00M | $15.20M | $2.585M |
| YoY Change | -9.94% | 484.62% | 186.27% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $108.5M | $120.9M | $76.13M |
| Total Long-Term Assets | $15.00M | $15.20M | $2.585M |
| Total Assets | $123.5M | $136.1M | $78.72M |
| YoY Change | 50.14% | 72.94% | -13.63% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.000M | $1.900M | $2.098M |
| YoY Change | 63.67% | -9.52% | 3.81% |
| Accrued Expenses | $7.600M | $6.700M | $6.120M |
| YoY Change | 45.54% | 0.0% | 41.4% |
| Deferred Revenue | $1.108M | ||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $9.600M | $8.600M | $9.885M |
| YoY Change | 18.52% | -13.13% | 12.92% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $12.90M | $13.20M | $15.32M |
| YoY Change | -7.86% | 1601.67% | |
| Total Long-Term Liabilities | $12.90M | $13.20M | $15.32M |
| YoY Change | -7.86% | 1601.67% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $9.600M | $8.600M | $9.885M |
| Total Long-Term Liabilities | $12.90M | $13.20M | $15.32M |
| Total Liabilities | $22.50M | $21.80M | $25.66M |
| YoY Change | 1.81% | 120.2% | 164.92% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$216.9M | ||
| YoY Change | 37.75% | ||
| Common Stock | $35.00K | ||
| YoY Change | 34.62% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $101.0M | $114.3M | $68.81M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $123.5M | $136.1M | $94.39M |
| YoY Change | 50.06% | 72.94% | 3.56% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 | 2017 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$14.42M | -$61.83M | -$13.42M |
| YoY Change | 30.76% | 4.04% | 42.55% |
| Depreciation, Depletion And Amortization | $351.0K | $1.778M | $400.0K |
| YoY Change | -37.66% | 26.82% | 566.67% |
| Cash From Operating Activities | -$13.43M | -$58.84M | -$11.84M |
| YoY Change | 11.59% | 12.31% | -16.09% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $9.000K | $415.0K | $0.00 |
| YoY Change | 251.69% | -100.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $16.16M | -$44.39M | -$19.84M |
| YoY Change | 1715.73% | -301.77% | 88.77% |
| Cash From Investing Activities | $16.15M | -$44.81M | -$19.84M |
| YoY Change | 1708.17% | -304.75% | 85.25% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $21.70M | ||
| YoY Change | -49.81% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 56.00K | 101.6M | 43.21M |
| YoY Change | 21.74% | 134.79% | -10902.5% |
| NET CHANGE | |||
| Cash From Operating Activities | -13.43M | -58.84M | -11.84M |
| Cash From Investing Activities | 16.15M | -44.81M | -19.84M |
| Cash From Financing Activities | 56.00K | 101.6M | 43.21M |
| Net Change In Cash | 2.774M | -2.036M | 11.53M |
| YoY Change | -125.0% | -115.95% | -145.72% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$13.43M | -$58.84M | -$11.84M |
| Capital Expenditures | $9.000K | $415.0K | $0.00 |
| Free Cash Flow | -$13.44M | -$59.26M | -$11.84M |
| YoY Change | 11.67% | 12.85% | -14.88% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q4 | us-gaap |
Assets
Assets
|
78718000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1884000 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2098000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5661000 | |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6120000 | |
| CY2017Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
1108000 | |
| CY2018Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1056000 | |
| CY2017Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
559000 | |
| CY2018 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2018 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | |
| CY2018 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2018 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2018 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2019Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
51040615 | |
| CY2018Q2 | dei |
Entity Public Float
EntityPublicFloat
|
92932233 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28810000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29724000 | |
| CY2018Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
89569000 | |
| CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
44738000 | |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
294000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2481000 | |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1377000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
120860000 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
76133000 | |
| CY2018Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
13849000 | |
| CY2017Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
472000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
605000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
424000 | |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
33000 | |
| CY2018Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
828000 | |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
1656000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
136142000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8601000 | |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
9885000 | |
| CY2018Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
13196000 | |
| CY2018 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
| CY2018 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2840000 | |
| CY2017 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
5341000 | |
| CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-63182000 | |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-59973000 | |
| CY2018 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
872000 | |
| CY2017 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
641000 | |
| CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
478000 | |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-100000 | |
| CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-61832000 | |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-59432000 | |
| CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.61 | |
| CY2017 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.34 | |
| CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38495103 | |
| CY2017 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25407943 | |
| CY2018 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
3000 | |
| CY2017 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
20000 | |
| CY2018 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-61829000 | |
| CY2017 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-59412000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
81456000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
31000 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2965000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
43000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
767000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
42884000 | |
| CY2017 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
20000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
21000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3526000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
55000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
80126000 | |
| CY2018 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
3000 | |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-61832000 | |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-59432000 | |
| CY2018 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1778000 | |
| CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1402000 | |
| CY2018 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
438000 | |
| CY2017 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-178000 | |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3526000 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2965000 | |
| CY2018 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
889000 | |
| CY2017 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
767000 | |
| CY2018 | pti |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
-22000 | |
| CY2017 | pti |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
-66000 | |
| CY2018 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-41000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-668000 | |
| CY2018 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
1104000 | |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-2682000 | |
| CY2018 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-33000 | |
| CY2017 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-35000 | |
| CY2018 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-204000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
67000 | |
| CY2018 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-239000 | |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1481000 | |
| CY2018 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3000 | |
| CY2017 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1848000 | |
| CY2018 | pti |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1269000 | |
| CY2017 | pti |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-1294000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-58844000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-52395000 | |
| CY2018 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
111240000 | |
| CY2017 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
61220000 | |
| CY2018 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
66850000 | |
| CY2017 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
83221000 | |
| CY2018 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
415000 | |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
118000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-44805000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
21883000 | |
| CY2018 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
21703000 | |
| CY2018 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
21000 | |
| CY2017 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
31000 | |
| CY2018 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
431000 | |
| CY2017 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
35000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
101613000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
43279000 | |
| CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2036000 | |
| CY2017 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
12767000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
31674000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
18907000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
29638000 | |
| CY2018 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">Nature of the Business </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteostasis Therapeutics, Inc. (the “Company”) was incorporated in Delaware on December 13, 2006. The Company is a clinical stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (“CF”) and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. CF is a disease caused by defects in the function or abundance of cystic fibrosis transmembrane conductance regulator (“CFTR”). The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. Upon discovery of amplifiers, a novel class of CFTR modulators, the Company has exploited its novel mechanism of action as a drug screening tool and has subsequently identified correctors and potentiators to be developed as part of combination therapies. Investigational agents representative of all three classes of CFTR modulators are currently in clinical development and include <font style="Background-color:#FFFFFF;color:#000000;">PTI-801 a third generation CFTR corrector, PTI-808, a CFTR potentiator, and </font>PTI-428, a CFTR amplifier<font style="Background-color:#FFFFFF;color:#000000;">. The Company is pursuing proprietary dual combination of PTI-801 and PTI-808, and triple combination of PTI-801, PTI-808 and PTI-428 as product opportunities. Additionally, the Company believes that both PTI-801 and PTI-428 have potential as add-on therapy to current and future standard-of-care CFTR modulator treatments. The Company is developing and, if approved, intends to commercialize their own therapies, including add-on and proprietary combination therapies for CF patients who have at least one F508del mutation, representing the majority of the patient population.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC 205-40, <font style="font-style:italic;">Going Concern</font> (“ASC 205-40”), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. As of December 31, 2018, the Company had an accumulated deficit of $277.5 million. The Company has incurred losses and negative cash flows from operations since its inception, including net losses of $61.8 million and $59.4 million for the years ended December 31, 2018 and 2017, respectively. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. The Company currently expects that its cash, cash equivalents and short-term investments of $118.4 million will be sufficient to fund its operating expenses and capital requirements, based upon its current operating plan, for at least 12 months from the date that these financial statements are issued. However, additional funding will be necessary to complete the funding of critical path activities in 2020. The Company will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, and the Company may not be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company reduced headcount through the elimination of 13 positions. As a result of this action, which was completed in the fourth quarter of 2017, the Company incurred one-time severance and related costs of $0.2 million in the fourth quarter of 2017.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Public Offerings </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter 2018, the Company completed a follow-on public offering whereby the Company sold 12,650,000 shares of common stock at a public offering price of $6.75 per share, which included 1,650,000 shares issued pursuant to the exercise by the underwriters of their option to purchase additional shares of common stock. The Company received net proceeds of approximately $80.1 million, after deducting underwriting discounts and commissions and other offering expenses. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company entered into a sales agreement with Leerink Partners LLC (“Leerink”) with respect to an at-the-market (“ATM”) offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, resulting in aggregate gross offering proceeds of up to $50.0 million. Leerink is not required to sell any specific amount but acts as the Company’s sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices. Common stock will be sold at prevailing market prices at the time of the sale; and as a result, prices may vary. The Company will pay Leerink up to 3% of the gross proceeds from any common stock sold through the sales agreement. As of December 31, 2018, the Company had sold an aggregate of 3,475,166 shares of its common stock for total net proceeds of approximately $21.6 million under the ATM program. At December 31, 2018, $27.6 million of common stock remains available for sale under the ATM. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company completed a follow-on public offering whereby the Company sold 9,200,000 shares of common stock at a public offering <font style="color:#000000;">price</font> of $5.00 per share, which included 1,200,000 shares issued pursuant to the exercise of the underwriters of their option to purchase additional shares of common stock. The Company received net proceeds of <font style="color:#000000;">$42.9 million after deducting underwriting discounts and commissions and other offering expenses.</font><font style="font-size:12pt;color:#000000;"> </font>  </p> | |
| CY2018 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses, including clinical trials, stock-based compensation, determining the value of the operating lease right of use asset and the valuation of the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p> | |
| CY2018 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Customers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company mitigates its risk with respect to cash, cash equivalents and short-term investments by maintaining its balances at two accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company’s only customer in 2018 was Astellas Pharma Inc. (“Astellas”) and as of December 31, 2018, the Astellas Agreement (as defined below) had completed and all amounts were paid in full. </p> | |
| CY2018 | us-gaap |
Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
|
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values.</p> | |
| CY2018 | us-gaap |
Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Embedded Derivatives </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists associated with an alternate payment option upon change of control within the research, development and commercialization agreement with Cystic Fibrosis Foundation, Inc. (“CFF”) (see Note 4). The embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. The derivative liability is marked-to-market every reporting period. Changes in fair value of the derivative liability are recognized as a component of other income (expense), net, in the accompanying statement of operations. </p> | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
118400000 | |
| CY2017Q4 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
|
13 | |
| CY2017Q4 | us-gaap |
Severance Costs1
SeveranceCosts1
|
200000 | |
| CY2018Q4 | pti |
Number Of Accredited Financial Institutions
NumberOfAccreditedFinancialInstitutions
|
2 | |
| CY2017 | pti |
Increase Decrease In Restricted Cash Short Term
IncreaseDecreaseInRestrictedCashShortTerm
|
300000 | |
| CY2017 | pti |
Increase Decrease In Restricted Cash Long Term
IncreaseDecreaseInRestrictedCashLongTerm
|
800000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
4000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
89569000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
44740000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
44738000 | |
| CY2018 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2017 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.93 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
6.03 | |
| CY2017 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | |
| CY2018Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2017Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2018Q4 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2017Q4 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2018Q4 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2017Q4 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2018Q4 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2017Q4 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2018 | pti |
Fair Value Option Methodology And Assumption
FairValueOptionMethodologyAndAssumption
|
Monte-Carlo simulation analysis | |
| CY2018Q4 | us-gaap |
Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
|
0 | |
| CY2017Q4 | us-gaap |
Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
|
0 | |
| CY2018Q4 | pti |
Prepaid Clinical Manufacturing And Scientific Expenses Current
PrepaidClinicalManufacturingAndScientificExpensesCurrent
|
1660000 | |
| CY2017Q4 | pti |
Prepaid Clinical Manufacturing And Scientific Expenses Current
PrepaidClinicalManufacturingAndScientificExpensesCurrent
|
568000 | |
| CY2018Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
108000 | |
| CY2017Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
55000 | |
| CY2018Q4 | pti |
Other Prepaid Expenses And Other Current Assets
OtherPrepaidExpensesAndOtherCurrentAssets
|
713000 | |
| CY2017Q4 | pti |
Other Prepaid Expenses And Other Current Assets
OtherPrepaidExpensesAndOtherCurrentAssets
|
754000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3300000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3625000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2695000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3201000 | |
| CY2016 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1400000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2746000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1542000 | |
| CY2018Q4 | pti |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
1965000 | |
| CY2017Q4 | pti |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
3930000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
799000 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
556000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
151000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
92000 | |
| CY2018 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
Each share of common stock entitles the holder to one vote for the election of directors and on all matters submitted to a vote of the Company’s stockholders. | |
| CY2018Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
4645322 | |
| CY2017Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3741251 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0268 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0200 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y11M15D | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7847 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7518 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2838558 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1004025 | |
| CY2018 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
8775 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
675132 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3158676 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
3075426 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1697979 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.69 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.22 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.43 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
5.14 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
6.44 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M6D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y6M10D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y8M1D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y11M1D | |
| CY2017Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
|
3213000 | |
| CY2018Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
|
471000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
399000 | |
| CY2018Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
280000 | |
| CY2018Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
3.22 | |
| CY2017Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
4.57 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
3500000 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
2500000 | |
| CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4415000 | |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3732000 | |
| CY2018Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
4300000 | |
| CY2018 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y7D | |
| CY2018 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2017 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.340 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.061 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.056 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.039 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.032 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
|
0.006 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
-0.004 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
-0.007 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.312 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.020 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.401 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
68219000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
52861000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
12799000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
9232000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
2066000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
1583000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
83084000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
63676000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
82965000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
63660000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
119000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
16000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
119000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
16000 | |
| CY2018 | pti |
Tax Cuts And Jobs Act Of2017 Limitation Of Net Operating Loss Deductions As Percentage Of Current Year Taxable Income
TaxCutsAndJobsActOf2017LimitationOfNetOperatingLossDeductionsAsPercentageOfCurrentYearTaxableIncome
|
0.80 | |
| CY2017 | pti |
Tax Cuts And Jobs Act Of2017 Change In Tax Rate Decrease In Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateDecreaseInDeferredTaxAssets
|
24000000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
252600000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
240100000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
|
19305000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
62442000 | |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
|
1218000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2018 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3322101 | |
| CY2017 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2838558 | |
| CY2017Q3 | us-gaap |
Area Of Real Estate Property
AreaOfRealEstateProperty
|
30000 | |
| CY2018 | pti |
Lessee Leasing Arrangements Operating Lease Expiration Date
LesseeLeasingArrangementsOperatingLeaseExpirationDate
|
2018-05 | |
| CY2018Q1 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P10Y | |
| CY2018Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P7Y | |
| CY2018 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2232000 | |
| CY2017 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1143000 | |
| CY2018 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
366000 | |
| CY2018 | us-gaap |
Lease Cost
LeaseCost
|
2598000 | |
| CY2017 | us-gaap |
Lease Cost
LeaseCost
|
1143000 | |
| CY2018 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1634000 | |
| CY2017 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1344000 | |
| CY2018 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
14252000 | |
| CY2018Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P9Y4M2D | |
| CY2017Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4M2D | |
| CY2018Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0450 | |
| CY2017Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0406 | |
| CY2018Q1 | us-gaap |
Revenues
Revenues
|
942000 | |
| CY2018Q2 | us-gaap |
Revenues
Revenues
|
843000 | |
| CY2018Q3 | us-gaap |
Revenues
Revenues
|
1055000 | |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8400000 | |
| CY2018Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12604000 | |
| CY2018Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15591000 | |
| CY2018Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13717000 | |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3823000 | |
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3957000 | |
| CY2018Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4150000 | |
| CY2018Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3780000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
12223000 | |
| CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
16561000 | |
| CY2018Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
19741000 | |
| CY2018Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
17497000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11281000 | |
| CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15718000 | |
| CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-18686000 | |
| CY2018Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17497000 | |
| CY2018Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
165000 | |
| CY2018Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
194000 | |
| CY2018Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
171000 | |
| CY2018Q4 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
342000 | |
| CY2018Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
90000 | |
| CY2018Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
46000 | |
| CY2018Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
87000 | |
| CY2018Q4 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
255000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11026000 | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15478000 | |
| CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18428000 | |
| CY2018Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16900000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.32 | |
| CY2018Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.43 | |
| CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.50 | |
| CY2018Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.36 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
34474004 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36009109 | |
| CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36694957 | |
| CY2018Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
46687910 | |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
1021000 | |
| CY2017Q2 | us-gaap |
Revenues
Revenues
|
1147000 | |
| CY2017Q3 | us-gaap |
Revenues
Revenues
|
1551000 | |
| CY2017Q4 | us-gaap |
Revenues
Revenues
|
1622000 | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13108000 | |
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15370000 | |
| CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12894000 | |
| CY2017Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12282000 | |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3170000 | |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2902000 | |
| CY2017Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2741000 | |
| CY2017Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2847000 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
16278000 | |
| CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
18272000 | |
| CY2017Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
15635000 | |
| CY2017Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
15129000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15257000 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17125000 | |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14084000 | |
| CY2017Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13507000 | |
| CY2017Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
191000 | |
| CY2017Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
169000 | |
| CY2017Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
155000 | |
| CY2017Q4 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
126000 | |
| CY2017Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-30000 | |
| CY2017Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-2000 | |
| CY2017Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-25000 | |
| CY2017Q4 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-43000 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15096000 | |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16958000 | |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13954000 | |
| CY2017Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13424000 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.60 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.68 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.56 | |
| CY2017Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.51 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25020337 | |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25040131 | |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25093344 | |
| CY2017Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
26465521 |
